Multi-layered Gag-specific immunodominant responses contribute to improved viral control in the CRF01_AE subtype of HIV-1-infected MSM subjects

Table 1 Subject demographics and clinical data

PID	Subtypes^a	Median CD4 counts^b	Set point^c	HLA types
PID	Subtypes^a	Median CD4 counts^b	Set point^c	HLA-A	HLA-B	HLA-C
Subject 1	CRF01_AE	671	2.84	01,33	07,35	07,12
Subject 2	CRF01_AE	507	2.95	02,29	27,40	02,03
Subject 3	CRF01_AE	578	3.53	03,24	15,49	07,08
Subject 4	CRF01_AE	657	3.58	02,24	13,40	03,08
Subject 5	CRF01_AE	670	3.75	02,32	13,44	03,04
Subject 6	CRF01_AE	557	4.29	01,02	15,57	06,06
Subject 7	CRF01_AE	498	4.30	02,26	38,48	08,12
Subject 8	CRF01_AE	407	4.43	02,11	13,13	02,03
Subject 9	CRF01_AE	614	4.49	02,80	15,15	03,03
Subject 10	CRF01_AE	416	4.50	02,30	13,46	01,06
Subject 11	CRF01_AE	254	4.61	02,02	15,58	03,03
Subject 12	CRF01_AE	695	4.62	02,11	40,46	01,08
Subject 13	CRF01_AE	280	5.08	02,30	13,13	06,07
Subject 14	CRF01_AE	440	5.20	02,11	15,40	03,07
Subject 15	CRF01_AE	664	5.38	11,11	35,54	01,01

^aSubtypes were all CRF01_AE cluster II
^bMedian CD4 counts were calculated from at least 3 time points from 3 months to 1 year post infection
^cSet point was the average viral load from 120 days to 1 year post infection (at least 3 time points)

ISSN: 1471-2172